Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy

<p>Abstract</p> <p>Background</p> <p>Antisense-mediated exon skipping is currently one of the most promising therapeutic approaches for Duchenne muscular dystrophy (DMD). Using antisense oligonucleotides (AONs) targeting specific exons the DMD reading frame is restored...

Full description

Bibliographic Details
Main Authors:	van Ommen Gert-Jan B, Janson Anneke AM, Aartsma-Rus Annemieke, van Deutekom Judith CT
Format:	Article
Language:	English
Published:	BMC 2007-07-01
Series:	BMC Medical Genetics
Online Access:	http://www.biomedcentral.com/1471-2350/8/43

Similar Items

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
by: van Ommen Gert-Jan B, et al.
Published: (2008-12-01)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
by: van Ommen Gert Jan B, et al.
Published: (2011-04-01)

Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Silvana M G Jirka, et al.
Published: (2015-01-01)

Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy.
by: Ruurd C Verheul, et al.
Published: (2016-01-01)

Novel Cationic Carotenoid Lipids as Delivery Vectors of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Vassilia Partali, et al.
Published: (2012-01-01)

Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
by: Limin Cao, et al.
Published: (2014-01-01)

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy
by: Bovolenta, M., et al.
Published: (2022)

Modulation of exon skipping using phosphorodiamidate morpholino antisense oligonucleotides in murine models of Duchenne muscular dystrophy
by: McCulley, Caroline Heather
Published: (2009)

Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy
by: Bovolenta, M., et al.
Published: (2022)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
by: Monika Hiller, et al.
Published: (2018-01-01)

Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
by: Limin Cao, et al.
Published: (2018-01-01)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
by: Naoki Watanabe, et al.
Published: (2018-12-01)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
by: Yoshitsugu Aoki, et al.
Published: (2013-01-01)

Correction: Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
by: PLOS ONE Staff
Published: (2019-01-01)

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges
by: Yusuke Echigoya, et al.
Published: (2018-12-01)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
by: Yuko Shimizu-Motohashi, et al.
Published: (2018-06-01)

Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
by: Quynh Nguyen, et al.
Published: (2017-10-01)

Antisense therapies for Duchenne muscular dystrophy
by: Rabinowitz, Adam Howard
Published: (2007)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
by: Christa L Tanganyika-de Winter, et al.
Published: (2012-01-01)

Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
by: Pablo Beckers, et al.
Published: (2021-02-01)

Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP)
by: A Seda Yılmaz-Eliş, et al.
Published: (2013-01-01)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014-01-01)

In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
by: Yusuke Echigoya, et al.
Published: (2015-01-01)

Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy
by: Sako, Yukiya
Published: (2017)

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
by: Jeroen Bremer, et al.
Published: (2016-01-01)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
by: Sarah Engelbeen, et al.
Published: (2021-01-01)

Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East
by: Fouad Alghamdi, et al.
Published: (2021-09-01)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy.
by: Bauke Kogelman, et al.
Published: (2018-01-01)

Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients
by: Marthe Helene Solberg, et al.
Published: (2020-12-01)

RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect
by: Claire Domenger, et al.
Published: (2018-03-01)

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
by: Claudia Brogna, et al.
Published: (2019-01-01)

A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
by: Gemma L Walmsley, et al.
Published: (2010-01-01)

Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene
by: Kane L Greer, et al.
Published: (2014-01-01)

Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
by: Chantal Beekman, et al.
Published: (2018-01-01)

The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
by: Dominic Scaglioni, et al.
Published: (2021-01-01)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
by: Alison M Blain, et al.
Published: (2018-01-01)

Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
by: Claudia Brogna, et al.
Published: (2019-01-01)

Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (1989-05-01)

A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy.
by: Ingrid E C Verhaart, et al.
Published: (2019-01-01)

Molecular Diagnosis of Duchenne/Becker Muscular Dystrophy: Analysis of Exons Deletion and Carrier Detection
by: Mohammad Taghi Akbari, et al.
Published: (2010-01-01)

Cannot write session to /tmp/vufind_sessions/sess_21sbocn6c6l11t7crhq4uc1mss